Current Report Filing (8-k)

Date : 06/19/2019 @ 1:30PM
Source : Edgar (US Regulatory)
Stock : Novabay Pharmaceuticals, Inc. (NBY)
Quote : 1.08  -0.18 (-14.29%) @ 7:27PM

Current Report Filing (8-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of earliest event reported: June 17, 2019

 

NovaBay Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-33678

68-0454536

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(I.R.S. Employer

Identification No.)

 

2000 Powell Street, Suite 1150, Emeryville, CA     94608

(Address of Principal Executive Offices) (Zip Code)

 

(510) 899-8800

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

 

Trading Symbol(s)

 

Name of Each Exchange On Which Registered

Common Stock, par value $0.01 per share

 

NBY

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.01—Entry into a Material Definitive Agreement .

 

On June 17, 2019, NovaBay Pharmaceuticals, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) for the sale of an aggregate of 1,371,427 shares of the Company’s common stock, par value $0.01 per share (the “ Shares ”), and warrants (the “ Warrants ”) exercisable for 1,371,427 Shares (the “ Warrant Shares ”) to accredited investors for an aggregate purchase price of $2,400,000 (the “ Private Placement ”). For every one (1) Share purchased at $1.75 per share, each purchaser will receive a Warrant to purchase one Share, with such Warrants having a one (1)-year term and an exercise price of $0.87, callable by the Company if the closing price of the Company’s common stock, as reported on the NYSE American, is $1.00 or greater. The Private Placement is expected to close in June 2019, following the satisfaction of certain closing conditions specified in the Purchase Agreement.

 

The purchasers include Xiao Rui Liu, who has agreed to purchase 571,428 Shares and 571,428 Warrants, Hai Dong Pang, who has agreed to purchase 228,571 Shares and 228,571 Warrants, and Ping Huang, who has agreed to purchase 571,428 Shares and 571,428 Warrants (the “ Purchasers ”). China Kington Asset Management Co. Ltd. (the “ China Kington ”) has agreed to serve as placement agent in exchange for a commission equal to six percent (6%) of the gross proceeds received by the Company upon the closing of the Private Placement. A description of the material relationships between the Company and China Kington was previously reported in the Company’s Annual Report on Form 10-K filed with the SEC on March 29, 2019, and such description is incorporated herein by reference.

 

The Purchase Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Purchasers (including for certain liabilities under the Securities Act of 1933, as amended (the “ Securities Act ”)), and other obligations of the parties and termination provisions. The foregoing description of the terms of the Purchase Agreement and the Warrants does not purport to be complete and is qualified in its entirety by reference to the Purchase Agreement and the Form of Warrants, which are attached hereto as Exhibit 10.1 and Exhibit 4.1 , respectively, and are incorporated herein by reference. The Purchase Agreement and the Form of Warrants has been included to provide investors and security holders with information regarding their terms, and they are not intended to provide any other factual information about the Company. The representations, warranties and covenants contained in the Purchase Agreement were made only for purposes of such agreement as of a specific date and were solely for the benefit of the parties to such agreement. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to the agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors.

 

The Shares, Warrants and Warrant Shares to be issued by the Company pursuant to the Purchase Agreement have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Company is relying on the private placement exemption from registration provided by Section 4(a)(2) of the Securities Act and by Rule 506 of Regulation D, and in reliance on similar exemptions under applicable state laws.

 

Item 3.02—Unregistered Sales of Equity Securities .

 

The information set forth in Item 1.01 of the Current Report on Form 8-K is incorporated by reference into this Item 3.02.

 

 

 

 

Item 9.01.     Financial Statements and Exhibits.

 

(d)           Exhibits .

 

 

Exhibit No.

 

Description

     

4.1

 

Form of Warrant

10.1

 

Securities Purchase Agreement, dated June 17, 2019

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NovaBay Pharmaceuticals, Inc.

 
       
       
 

By:

/s/ Justin Hall

 
   

Justin Hall

 
   

President & Chief Executive Officer and General Counsel

 

 

 

Dated: June 19, 2019

 

Novabay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Novabay Pharmaceuticals Charts.

Novabay Pharmaceuticals (AMEX:NBY)
Intraday Stock Chart

Today : Thursday 18 July 2019

Click Here for more Novabay Pharmaceuticals Charts.

Latest NBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.